Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Core Viewpoint - Instil Bio and ImmuneOnco are collaborating to host an investor and research analyst breakfast to discuss advancements in the PD-(L)1xVEGF bispecific antibody landscape and recent clinical trial updates [1][2] Company Overview - ImmuneOnco is a clinical-stage biotech company focused on the discovery and development of biologics for treating cancers, autoimmune diseases, and metabolic diseases, with over 10 assets in development, including one in phase III [3] - Instil Bio is a clinical-stage biopharmaceutical company developing novel therapies, with its lead asset AXN-2510 being a PD-L1xVEGF bispecific antibody aimed at treating multiple solid tumors [4]